ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Ascendis Pharma A/S
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 20-F on Feb 11, 2026
$229.95+4.70 (+2.09%)
Close on Oct 19, 2026
Ownership
Who owns Ascendis Pharma A/S's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
9 buys · 3 sales
Net sold $4.74M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Rajeev Shah | 9,710,428 | 16.10% | 13G (passive) amendment | Sep 30, 2024 |
| T. Rowe Price Investment Management, Inc. | 6,506,219 | 10.50% | 13G (passive) amendment | Apr 30, 2026 |
| Westfield Capital Management Company, L.P. | 5,185,696 | 8.48% | 13G (passive) amendment | Dec 31, 2025 |
| Avoro Capital Advisors LLC | 4,988,888 | 8.20% | 13G (passive) amendment | Sep 30, 2024 |
| FMR LLC | 4,646,943 | 8.00% | 13G (passive) amendment | Mar 31, 2025 |
| Abigail P. Johnson | 3,852,101 | 6.60% | 13G (passive) amendment | Mar 31, 2026 |
| Janus Henderson Group PLC | 3,719,452 | 6.00% | 13G (passive) amendment | Mar 31, 2026 |
| Artisan Partners Holdings LP | 3,225,885 | 5.20% | 13G (passive) amendment | Dec 31, 2025 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mads Bodenhoff | SVP & PAO | 0 | – | Sep 9, 2026 |
| Scott Thomas Smith | EVP & Chief Financial Officer | 4,367 | 0.01% | Jun 2, 2026 |
| Flemming Steen Jensen | See Remarks | 0 | – | May 12, 2026 |
| Kennett Sprogoe | See Remarks | 19,570 | 0.03% | Mar 18, 2026 |
| Aimee Shu | EVP & Chief Medical Officer | 0 | – | Mar 18, 2026 |
| Jay Donovan Wu | EVP & President US Market | 1,068 | 0.00% | Mar 18, 2026 |
| Michael Wolff Jensen | EVP, Chief Legal Officer | – | – | Mar 18, 2026 |
| Anni Lotte Kirstine Sonderbjerg Pedersen | EVP & Chief Admin Officer | 19,460 | 0.03% | Mar 18, 2026 |
| Jean Jacques Bienaime | Director | 2,900 | 0.00% | Sep 28, 2026 |
| Lars Holtug | Director | 4,000 | 0.01% | Sep 3, 2026 |
| Albert Cha | Director | 3,730 | 0.01% | Mar 18, 2026 |
| Siham Imani | Director | 2,317 | 0.00% | Mar 18, 2026 |
| Jan Moller Mikkelsen | Director | 453,403 | 0.73% | Mar 18, 2026 |
| William Fairey | Director | 2,117 | 0.00% | Mar 18, 2026 |
| Lisa Morrison | Director | 1,572 | 0.00% | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mads Bodenhoff SVP & PAO | Sep 8, 2026 | Sale | −3,000 | $270.19 | $810.57K | 0 |
| Mads Bodenhoff SVP & PAO | Sep 8, 2026 | Option exercise | +3,000 | $110.00 | $330.00K | 3,000 |
| Lars Holtug Director | Sep 2, 2026 | Sale | −236 | $264.13 | $62.33K | 4,000 |
| Jean Jacques Bienaime Director | Aug 14, 2026 | Buy | +900 | $246.91 | $222.22K | 2,900 |
| Jean Jacques Bienaime Director | Aug 14, 2026 | Buy | +1,100 | $245.85 | $270.44K | 2,000 |
| Scott Thomas Smith EVP & Chief Financial Officer | Jun 2, 2026 | Buy | +100 | $219.00 | $21.90K | 4,367 |
| Scott Thomas Smith EVP & Chief Financial Officer | May 29, 2026 | Buy | +250 | $223.32 | $55.83K | 4,267 |
| Jean Jacques Bienaime Director | May 29, 2026 | Buy | +200 | $222.30 | $44.46K | 800 |
| Jean Jacques Bienaime Director | May 29, 2026 | Buy | +100 | $223.50 | $22.35K | 900 |
| Jean Jacques Bienaime Director | May 29, 2026 | Buy | +200 | $223.76 | $44.75K | 600 |
| Jean Jacques Bienaime Director | May 26, 2026 | Buy | +200 | $236.24 | $47.25K | 200 |
| Jean Jacques Bienaime Director | May 26, 2026 | Buy | +200 | $239.37 | $47.87K | 400 |
| Flemming Steen Jensen See Remarks | May 11, 2026 | Sale | −19,460 | $238.49 | $4.64M | 0 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Mads Bodenhoff Officer | Sep 8, 2026 | 3,000 | $810.56K | Sep 8, 2026 | Warrant exercise |
| Lars Holtug Director | Sep 2, 2026 | 236 | $62.33K | Sep 2, 2026 | SHARE PLAN ACCOUNT |
| Flemming Steen Jensen Officer, EXECUTIVE VP HEAD OF PRODUCT SUPPLY AND QUALITY | May 11, 2026 | 19,460 | $4.64M | May 11, 2026 | SHARE PLAN ACCOUNT |
| Stina Singel Officer | Mar 9, 2026 | 3,782 | $907.68K | Mar 9, 2026 | Warrant exercise |
| Scott Thomas Smith Officer | Mar 6, 2026 | 10,000 | $2.40M | Mar 5, 2026 | Warrant exercise |
| Mads Bodenhoff Officer | Mar 6, 2026 | 10,000 | $2.38M | Mar 6, 2026 | Warrant exercise |
| Moller Mikkelsen Jan CEO, Officer | Mar 5, 2026 | 94,000 | $22.69M | Mar 5, 2026 | Warrant Exercise |
| Scott Thomas Smith Officer | Mar 5, 2026 | 10,000 | $2.40M | Mar 5, 2026 | Warrant exercise |
| Aimee Shu Officer | Mar 5, 2026 | 5,583 | $1.32M | Mar 5, 2026 | Warrant exercise |
| Lisa Morrison Officer | Mar 4, 2026 | 10,105 | $2.39M | Mar 4, 2026 | Warrant exercise |
| Aimee Shu Officer, EXECUTIVE VICE PRESIDENT CHIEF MEDICAL OFFICER | Mar 4, 2026 | 7,290 | $1.74M | Mar 4, 2026 | SHARE PLAN ACCOUNT |
| William Fairey Director | Mar 2, 2026 | 1,800 | $435.76K | Mar 2, 2026 | RESTRICTED STOCK VESTING |
| Siham Imani Director | Mar 2, 2026 | 1,800 | $435.76K | Mar 2, 2026 | RESTRICTED STOCK VESTING |
| Scott Thomas Smith Officer, EXECUTIVE VP CHIEF FINANCIAL OFFICER | Mar 2, 2026 | 18,349 | $4.44M | Mar 2, 2026 | RESTRICTED STOCK VESTING |
| Michael Wolff Jensen Officer, EXECUTUVE VP CHIEF LEGAL OFFICER | Mar 2, 2026 | 18,349 | $4.44M | Mar 2, 2026 | RESTRICTED STOCK VESTING |